# Safety and Performance of a Pulsed Field Device for Global Mapping and Ablation of the Left Atrium for the Treatment of Atrial Fibrillation

Study · id `cardio:ct-nct05164107` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05164107](<https://clinicaltrials.gov/study/NCT05164107>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05164107

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 175 participants.

## Technical summary

Registry record NCT05164107. Allocation not applicable; no masking; primary purpose other. Start 2021-12-08 (actual); primary completion 2027-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose other
- Phase: Not applicable
- Enrolled: 175 participants (planned count; ClinicalTrials.gov record NCT05164107, source copy `cardio:ctgov-nct05164107-2026-01-30`, retrieved 2026-10-26)
- Started: 2021-12-08 (actual) (ClinicalTrials.gov record NCT05164107, source copy `cardio:ctgov-nct05164107-2026-01-30`, retrieved 2026-10-26)
- Primary completion: 2027-05 (anticipated) (ClinicalTrials.gov record NCT05164107, source copy `cardio:ctgov-nct05164107-2026-01-30`, retrieved 2026-10-26)
- Completion: 2027-05 (anticipated) (ClinicalTrials.gov record NCT05164107, source copy `cardio:ctgov-nct05164107-2026-01-30`, retrieved 2026-10-26)
- Countries: Czechia (ClinicalTrials.gov record NCT05164107, source copy `cardio:ctgov-nct05164107-2026-01-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05164107-2026-01-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Performance of a Pulsed Field Device for Global Mapping and Ablation of the Left Atrium for the Treatment of Atrial Fibrillation
- Acronym: PULSE-EU
- Condition: Atrial Fibrillation
- Intervention (Device): Globe Mapping and Pulsed Field Ablation System (Globe PF System)
- Lead sponsor: Kardium Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Kardium Inc. (`cardio:org-kardium-inc`)

## Provenance

Content hash: 250b43366bb7026147a8054b699797d96a71f4381826d3648f10c6512e5c9713
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
